Rational use of agonists and antagonists of luteinizing hormone- releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions

Advanced Drug Delivery Reviews

Volumn 28, Issue 1, 1997, Pages 157-169

  Schally, Andrew V ^a   Maria Comaru Schally, Ana ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer treatment; Depot preparations; LH RH agonists and antagonists; PLG Microcapsules; Sustained delivery systems

Indexed keywords

DRUG THERAPY; ENCAPSULATION; GYNECOLOGY; HORMONES; ONCOLOGY;

HORMONE AGONISTS; MICROSPHERES; SEX HORMONES;

CONTROLLED DRUG DELIVERY;

BUSERELIN; CETRORELIX; DETIRELIX; GANIRELIX; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GOSERELIN; ITURELIX; LEUPRORELIN; NAFARELIN; NANOPARTICLE; POLYGLACTIN; TRIPTORELIN;

BREAST CANCER; CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FEMALE; FERTILIZATION IN VITRO; GYNECOLOGIC DISEASE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MYOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION;

EID: 0343990053     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00056-2     Document Type: Review

References (89)

1. Schally A.V., Kastin A.J., Arimura A. Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies. Fertil. Steril. 22:1971;703-721.
2. A.V. Schally, A.M. Comaru-Schally, Hypothalamic and Other Peptide Hormones, in: J.F. Holland, E. Frei, III, R.C. Bast, Jr., D.E. Kufe, D.L. Morton, R.R. Weichselbaum, (Eds.), Cancer Medicine, 4th Edition, Williams and Wilkins Publishers, Baltimore, MD, 1997, pp. 1067-1086.
3. A.V. Schally, The use of LH-RH analogues in Gynaecology and Tumour Therapy, in: Belfort, P., Pinotti, J.A., Eskes, T.K.A.B. (Eds.) Advances in Gynaecology and Obstetrics, General Gynaecology., Vol. 6, Carnforth, England, Parthenon Publishing, 1989, pp. 3-20.
4. Vickery B.H. Comparison of the potential for therapeutic utilities with gonadotrophin-releasing hormone agonists and antagonists. Endocrine Rev. 7:1986;115-124.
5. Dutta A.S. Drugs of the Future. 13:1988;761-787.
6. Coy D.H., Horvath A., Nekola M.V., Coy E.J., Erchegyi J., Schally A.V. Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position. Endocrinology. 110:1982;1445-1447.
7. Debeljuk L., Schally A.V. Antifertility effects of a potent LH-RH antagonist in male and female rats. Int. J. Fertil. 31:1986;284-292.
8. Bajusz S., Kovacs M., Gazdag M., Bokser L., Karashima T., Csernus V.J., Janaky T., Guoth J., Schally A.V. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc. Natl. Acad. Sci.USA. 85:1988;1637-1641.
9. Bajusz S., Csernus V.J., Janaky T., Bokser L., Fekete M., Schally A.V. New antagonists of LHRH: II. Inhibition and potentiation of LHRH by closely related analogues. Intl. J. Peptide Prot. Res. 32:1988;425-435.
10. Reissmann T.H., Engel J., Kutscher B., Bernd M., Hilgard P., Peukert M., Szelenyi I., Reichert S., Gonzalez-Barcena D., Nieschiag E., Comaru-Schally A.M., Schally A.V. Drugs of the Future. 19:1994;228-237.
11. Gonzalez-Barcena D., Vadillo B.M., Garcia P.E., Guerra A.L., Cardenas C.I., Comaru-Schally A.M., Schally A.V. Inhibition of luteinizing hormone, follicle- stimulating hormone and sex-steroid levels in men and women with a potent antagonist analogue of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). Eur. J. Endocrinol. 131:1994;286-292.
12. Gonzalez-Barcena D., Vadillo B.M., Gomez O.F., Fuentes G.M., Cardenas C.I., Graaf S.A., Comaru-Schally A.M., Schally A.V. Responses to the Antagonistic Analogue of LH-RH (SB-75, Cetrorelix) in Patients with Benign Prostatic Hyperplasia and Prostate Cancer. The Prostate. 24:1994;84-92.
13. 6-) luteinizing hormone-releasing hormone from injectable microcapsules. Proc. Natl. Acad. Sci. USA. 81:1984;5845-5848.
14. R. Sharifi, M. Soloway, Leuprolide Study Group, Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J. Urology 143 (1990) 68-72.
15. Walker K.J., Walker R.F., Turkes A., Robertson J.R.F., Blamey R.W., Griffiths K., Nicholson R.I. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer. Eur. J. Cancer Clin. Oncol. 25:1989;651-654.
16. 10]LH-RH. Arzneimittel-Forschung/Drug Res. 40:1990;111-118.
17. Csernus V.J., Szende B., Schally A.V. Release of peptides from sustained delivery systems (microcapsules and microparticles) in vivo: A histological and immunohistological study. Intl. J. Peptide Prot. Res. 35:1990;557-565.
18. Reissmann T., Klenner T., Deger W., Hilgard P., McGregor G.P., Voigt K., Engel J. Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinizing hormone-releasing hormone. Eur. J. Cancer. 32:1996;1574-1579.
19. Bokser L., Bajusz S., Groot K., Schally A.V. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone- releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA. 87:1990;7100-7104.
20. Pinski J., Yano T., Groot K., Milovanovic S., Schally A.V. Comparison of Biological Effects of a Sustained Delivery System and Nonencapsulated LH-RH Antagonist SB-75 in Rats. Peptides. 13:1992;905-911.
21. Pinski J., Yano T., Szepeshazi K., Groot K., Schally A.V. Recovery of Pituitary-Gonadal Function in Male Rats after Long-Term Suppression Induced by a Single Injection of Microcapsules of LH-RH antagonist Cetrorelix (SB-75). J. Androl. 14:1993;164-169.
22. Halmos G., Schally A.V., Pinski J., Vadillo-Buenfil M., Groot K. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc. Natl. Acad. Sci. USA. 93:1996;2398-2402.
23. Pinski J., Lamharzi N., Halmos G., Groot K., Jungwirth A., Vadillo-Buenfil M., Kakar S.S., Schally A.V. Chronic Administration of the Luteinizing Hormone-Releasing Hormone (LH-RH) Decreases Gonadotrope Responsiveness and Pituitary LH-RH Receptor Messenger Ribonucleic Acid Levels in Rats. Endocrinology. 137:1996;3430-3436.
24. Behre H.M., Klein B., Steinmeyer E., McGregor G.P., Voigt K., Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J. Clin. Endocrinol. Metab. 75:1992;393-398.
25. Klingmuller D., Schepke M., Enzweiler C., Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol. 128:1993;15-18.
26. Andreyko J.L., Monroe S.E., Marshall L.A., Fluker M.R., Nerenberg C.A., Jaffe R.B. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, α subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (Detirelix). J. Clin. Endocrinol. Metab. 74:1992;399-405.
27. Pavlou S.N., Wakefield G.B., Island D.P., Hoffman P.G., LePage M.E., Chan R.I., Nerenberg C.A., Kovacs W.J. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men. J. Clin. Endocrinol. Metab. 64:1987;931-936.
28. Rabinovici J., Rothman P., Monroe S.E., Nerenberg C., Jaffe B. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin- releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J. Clin. Endocrinol. Metab. 75:1992;1220-1225.
29. Pavlou S.N., Wakefield G., Schlechter N.L., Lindner J., Souza K.H., Kamilaris T.C., Konidaris S., Rivier J.E., Vale W.W., Toglia M. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men. J. Clin. Endocrinol. Metab. 68:1989;446-454.
30. Jockenhovel F., Bhasin S., Steiner B.S., Rivier J.E., Vale W.W., Swerdloff R.S. Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men. J. Clin. Endocrinol. Metab. 66:1988;1065-1070.
31. Leal J.A., Williams R.F., Danforth D.R., Gordon K., Hodgen G.D. Prolonged duration of gonadotropin inhibition by a third generation GnRH antagonist. J. Clin. Endocrinol. Metab. 67:1988;1325-1327.
32. Matikainen T., Ding Y.-Q., Vergara M., Huhtaniemi I., Couzinet B., Schaison G. Differing responses to plasma bioactive and immunoreactive follicle-stimulating hormone and luteinizing hormone to gonadotropin-releasing hormone antagonist and agonist treatments in postmenopausal women. J. Clin. Endocrinol. Metab. 75:1992;820-825.
33. Bagatell C.J., Conn P.M., Bremmer W.J. Single-dose administration of the gonadotropin-releasing hormone antagonist Nal-Lys (antide) to healthy men. Fertil. Steril. 60:1993;80-85.
34. Olivenness F., Fanchin R., Bouchard P., de Ziegler D., Taieb J., Selva J., Frydman R. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril. 62:1994;468-476.
35. Dubourdieu S., Charbonnel B., d'Acremont M.-F., Carreau S., Spitz I.M., Bouchard P. Effect of Administration of a Gonadotropin-Releasing Hormone (GnRH) Antagonist (Nal-Glu) during the Periovuluatory Period: The Luteinizing Hormone Surge Requires Secretion of GnRH. J. Clin. Endocrinol. Metab. 78:1994;343-347.
36. Leroy I., d'Acremont M.F., Brailly-Tabard S., Frydman R., de Mouzon J., Bouchard P. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil. Steri.l. 62:1994;461-467.
37. Olivennes F., Fanchin R., Bouchard Ph., Taieb J., Selva J., Frydman R. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day eight of in vitro fertilization cycles: a pilot study. Human Reproduction. 10:1995;1382-1386.
38. Diedrich K., Diedrich C., Santos E., Zoll C., Al-Hasani S., Reissmann T., Krebs D., Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormne antagonist Cetrorelix during ovarian stimulation. Human Reprod. 9:1994;788-791.
39. Reissmann T., Felberbaum R., Diedrich K., Engel J., Comaru-Schally A.M., Schally A.V. Development and applications of LHRH antagonists in the treatment of infertility. Human Reprod. 10:1995;1974-1981.
40. Lemay A., Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary ovarian function by chronic intranasal administration of luteinizing hormone releasing hormone (LHRH) agonist. Fertil. Steril. 38:1982;376-379.
41. Henzl M.R., Corson S.L., Moghissi K., Buttram V.C., Bergquist C., Jacobson J. Administration of nasal Nafarelin as compared with oral danazol for endometriosis: a multicentre double-blind comparative clinical trial. N. Engl. J. Med. 318:1988;485-489.
42. 6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis. In. J. Fertil. 31:1986;11-27.
43. Filicori M., Hall D.A., Loughlin J.S., Rivier J., Vale W., Crowley F.W. A conservative approach to the management of uterine leiomyomas: Pituitary densensitization by a luteinizing hormone-releasing hormone analogue. Am. J. Obstet. Gynecol. 147:1983;726-727.
44. Healy D.L., Fraser H.M., Lawson S.L. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br. Med. J. 289:1984;1267-1268.
45. 6]LHRH. Lancet. 2:1986;45-51.
46. 6-LH-RH. Fertil. Steril. 48:1987;383-389.
47. George M., Lhomme C., Lefort J., Gras C., Comaru-Schally A.M., Schally A.V. Long-Term Use of an LH-RH Agonist in the Management of Uterine Leiomyomas: A Study of 17 Cases. Int. J. Fertil. 34:1989;19-24.
48. Kettel L.M., Murphy A.A., Morales A.J., Rivier J., Vale W., Yen S.S.C. Rapid regression of uteine Leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil. Steril. 60:1993;642-646.
49. D. Gonzalez-Barcena, E. Perez, I. Cardenas, M. Fuentes, M. Macedo, A.M. Comaru-Schally, A.V. Schally, Regression of Uterine Leiomyomas After the Administration of the New LH-RH Antagonist Cetrorelix (SB-75), in: 10th International Congress of Endocrinology (ICE'96), Abstract No. P3-385, June 12-15, San Francisco, California, 1996, p. 851.
50. Peters C.A., Walsh P.C. The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia. N. Engl. J. Med. 317:1987;599-604.
51. Gabrilove J.L., Levine A.C., Kirschenbaum A., Droller M. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. Clin. Endocrinol. Metab. 64:1986;1331-1333.
52. 6-LH-RH. Proc. Natl. Acad. Sci. USA. 78:1981;6509-6512.
53. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A., Comaru-Schally A.M., Schally A.V. Tumour growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists. Proc. Natl. Acad. Sci. USA. 79:1982;1658-1662.
54. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321:1989;419-424.
55. The Leuprolide Study Group, Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N. Engl. J. Med., 311 (1984) 1281-1286.
56. Sogani P.C., Fair W.R. Treatment of Advanced Prostatic Cancer. Urol. Clin. North Am. 14:1987;253-271.
57. Ahmann F.R., Citrin D.L., deHaan H.A., Guinan P., Jordan V.C., Kreis W., Scott M., Trump D.L. Zoladex: A sustained-release, monthly luteinizing hormone- releasing hormone analogue for the treatment of advanced prostate cancer. J. Clin. Oncol. 5:1987;912-917.
58. 6-LH-RH microcapsules in advanced prostatic carcinoma. Lancet. 2:1985;1201-1205.
59. Korkut E., Bokser L., Groot K., Schally A.V. Inhibition of growth of experimental Dunning R3327 rat prostate cancer with sustained delivery systems (microcapsules and microgranules) of an antagonist of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci.USA. 88:1991;844-848.
60. Redding T.W., Schally A.V., Radulovic S., Milovanovic S., Szepehazi K., Isaacs J. Sustained release formulation of LH-RH antagonists SB-75 inhibit proliferation and enhance the apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res. 52:1982;2538-2544.
61. Jungwirth A., Galvan G., Pinski J., Halmos G., Szepeshazi K., Cai R.-Z., Groot K., Schally A.V. LH-RH antagonist Cetrorelix (SB-75) and bombesin antagonist RC- 3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. The Prostate. 32:1997;164-172.
62. Gonzalez-Barcena D., Vadillo B.M., Cortez M.A., Fuentes G.M., Cardenas C.I., Comaru-Schally A.M., Schally A.V. Luteinizing hormone-releasing hormone antagonist Cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45:1995;275-281.
63. D. Gonzalez-Barcena, A.V. Schally, A.M. Comaru-Schally, A. Cortez-Morales, M. Vadillo-Buenfil, A. Molina-Ayala, Treatment of patients with advanced prostate cancer with LHRH antagonist Cetrorelix, in: M. Filicori, C. Flamigni, (Eds.), Treatment with GnRH analogues: Controversies and perspectives, eds., Proceedings of a Satelite Symposium of the 15th World Congress on Fertility and Sterility, September 15-16, Bologna, Italy, Parthenon Publishing, Carnforth, U.K., 1996, pp. 139-144.
64. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocrin. Rev. 11:1990;221-265.
65. Redding T.W., Schally A.V. Inhibition of mammary tumour growth in rats and mice by administration of agonistic and antagonistic analogues of luteinizing hormone- releasing hormone. Proc. Natl. Acad. Sci. USA. 80:1983;1459-1462.
66. Kaufmann M., Jonat W., Kleeburg U., Eirmann W., Janicke F., Hilfrich J., Kreienberg R., Albrecht M., Weitzel H.K., Schmid H., Strunz P., Schachner-Wunschmann E., Bastert G., Maass H. The German Zoladex trial group: Goserelin, a depot gonadotropin releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J. Clin. Oncol. 7:1989;1113-1119.
67. Plowman P.N., Nicholson R.I., Walker K.J. Responses in post-menopausal breast cancer with an LH-RH analogue (ICI 118,630). Eur. J. Cancer Clin. Oncol. 22:1986;746-749.
68. Williams M.R., Walker K.J., Turkes A., Blamey R.W., Nicholson R.I. The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Brit. J. Cancer. 53:1986;629-636.
69. G. Mathé, R. Keiling, G. Prevot, M.L. Vo Van, J. Gastiaburu, J.M. Vannetzel, R. Despax, C. Jasmin, F. Levi, M. Musset, D. Machover, R. Ribaud, J.L. Misset, LH-RH agonist: Breast and prostate cancer, in: J.G.M. Klijn, R. Paridaens, J.A. Foekens (Eds.), Hormonal manipulation of cancer: Peptides, growth factors, and new (anti) steroidal agents. New York, Raven Press, 1987, pp. 315-319.
70. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. J. Clin. Lab. Anal. 3:1989;137-147.
71. Monsonego J., Destable M.D., de Saint Florent G., Amouroux J., Kouyoumdjian J.C., Haour F., Breau J.L., Israel L., Comaru-Schally A.M., Schally A.V. Fibrocystic Disease of the Breast in Premenopausal Women: Histohormonal Correlation and Response to LHRH Analogue Treatment. Am. J. Obstet. Gynecol. 164:1991;1181-1189.
72. Szende B., Srkalovic G., Groot K., Lapis K., Schally A.V. Growth inhibition of mouse MXT mammary tumour by the luteinizing hormone-releasing hormone antagonist SB-75. J. Natl. Cancer Inst. 82:1990;513-517.
73. Yano T., Pinski J., Szepeshazi K., Halmos G., Radulovic S., Groot K., Schally A.V. Inhibitory effect of bombesin/gastrin releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 73:1994;1229-1238.
74. Emons G., Pahwa G.S., Brack C., Sturm R., Oberheuser F., Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur. J. Cancer. Clin. Oncol. 25:1989;215-221.
75. Emons G., Schally A.V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Human Reprod. 7:1994;1364-1379.
76. Yano T., Pinski J., Halmos G., Szepeshazi K., Groot K., Schally A.V. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc. Natl. Acad. Sci. USA. 91:1994;7090-7094.
77. 6]LHRH (Decapeptyl) microcapsules in advanced ovarian cancer. Br. Med. J. 296:1988;1229.
78. 6-LH-RH (decapeptyl) microcapsules. Biomed. Pharmacother. 42:1988;531-548.
79. Bruckner H.W., Motwani B.T. Treatment of advanced refactory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am. J. Obstet. Gynecol. 161:1989;1216-1218.
80. Emons G., Ortmann O., Teichert H.-M., Fassl H.G., Löhrs U., Kullander S., Kauppila A., Ayalon D., Schally A., Heinrich C., Oberheuser F. Luteinizing Hormone-Releasing Hormone agonist triptorelin in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer - A prospective double blinded randomized trial. Cancer. 78:1996;1452-1460.
81. Shirahige Y., Cook C.B., Pinski J., Halmos G., Nair R., Schally A.V. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Intl.J. Oncol. 5:1994;1031-1035.
82. 6]-luteinizing hormone-releasing hormone and epditermal growth factor in human endometrial carcinoma. Cancer Res. 50:1990;1841-1846.
83. Emons G., Schroder B., Ortmann O., Westphalen S., Schulz K.-D., Schally A.V. High affinity binding and direct antiproliferative effects of LH-RH agonists and Antagonists in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab. 77:1993;1458-1464.
84. Gallagher C.J., Oliver R.T.D., Oram D.H., Fowler C.G., Blake P.R., Mantell B.S., Slevin M.L., Hope-Stone H.F. A new treatment for endometrial cancer with gonadotropin-releasing hormone analogue. Br. J. Obstet. Gynaecol. 98:1991;1037-1041.
85. Szende B., Srkalovic G., Schally A.V., Lapis K., Groot K. Inhibitory effects of analogues of luteinizing hormone-releasing hormone (LH-RH) and somatostatin on pancreatic cancers in hamsters: Events which accompany tumour regression. Cancer. 65:1990;2279-2290.
86. Szende B., Srkalovic G., Groot K., Lapis K., Schally A.V. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with LH-RH antagonists or agonists. Cancer Res. 50:1990;3716-3721.
87. 6-LH-RH in advanced adenocarcinoma of pancreas. Lancet. 2:1986;154.
88. 6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed. Pharmacother. 43:1989;313-317.
89. Friess H., Büchler M., Krüger M., Beger H.G. Treatment of Duct Carcinoma of the Pancreas with the LH-RH Analogue Buserelin. Pancreas. 7:1992;516-521.